E
Elizabeth Harden
Researcher at University of North Carolina at Chapel Hill
Publications - 10
Citations - 1084
Elizabeth Harden is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Medical encyclopedia & Psychological intervention. The author has an hindex of 8, co-authored 10 publications receiving 966 citations.
Papers
More filters
Health literacy interventions and outcomes: an updated systematic review.
Nancy D. Berkman,Stacey L. Sheridan,Katrina E Donahue,David J Halpern,Anthony J. Viera,Karen Crotty,Audrey Holland,Michelle Brasure,Kathleen N. Lohr,Elizabeth Harden,Elizabeth Tant,Ina Wallace,Meera Viswanathan +12 more
TL;DR: Differences in health literacy level were consistently associated with increased hospitalizations, greater emergency care use, lower use of mammography, lower receipt of influenza vaccine, poorer ability to demonstrate taking medications appropriately, poorer able to interpret labels and health messages, and, among seniors, poorer overall health status and higher mortality.
Drug Therapy for Rheumatoid Arthritis in Adults: An Update
Katrina E Donahue,Daniel E Jonas,Richard A. Hansen,Robert Roubey,Beth Jonas,Linda J Lux,Gerald Gartlehner,Elizabeth Harden,Tania M Wilkins,Visali Peravali,Shrikant I. Bangdiwala,Andrea Yuen,Patricia Thieda,Laura C Morgan,Karen Crotty,Rishi J. Desai,Megan Van Noord +16 more
TL;DR: Treatment of patients with RA aims to control pain and inflammation and, ultimately, the goal is remission or at least low disease activity for all patients.
Journal ArticleDOI
Generalized Seizures Secondary to High-Dose Busulfan Therapy
TL;DR: Two patients without prior histories of neurologic disorders experienced generalized seizures while receiving high-dose busulfan as part of a preparative regimen for allogeneic bone marrow transplantation.
Journal ArticleDOI
Mixed Treatment Comparison of the Treatment Discontinuations of Biologic Disease-Modifying Antirheumatic Drugs in Adults with Rheumatoid Arthritis:
Rishi J. Desai,Richard A. Hansen,Jaya K. Rao,Tania M Wilkins,Elizabeth Harden,Andrea Yuen,Daniel E Jonas,Robert Roubey,Beth Jonas,Gerald Gartlehner,Linda J Lux,Katrina E Donahue +11 more
TL;DR: Differences in discontinuation rates were observed, generally favoring certolizumab, etanercept, and rituximab over other biologic DMARDs, and need to be further explored in head-to-head trials or well-conducted observational studies.